Labcorp agrees to buy select BioReference Health assets for $722 million plus earnout

Labcorp agreed to acquire select BioReference Health assets from OPKO Health for $722 million cash, subject to closing revenue adjustments. The deal includes the 4Kscore prostate cancer test, with up to $150 million in additional earnout payments tied to test revenue. Acquired assets include clinical and specialty testing businesses, with more than 80 additional patient service centers. The acquired business is expected to generate approximately $250 million in revenue in the first year following closing. Completion is subject to regulatory approvals and customary closing conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via (Ref. ID: 202610150730PR_NEWS_USPR_____DC72992) on October 15, 2026, and is solely responsible for the information contained therein. (C)